CD38 and hematopoietic and lymphoid cell neoplasm: Here, we examine how CD38-mediated mechanisms have been hijacked for tumorigenesis in the various hematological cancers and how these can be potentially exploited to enhance monoclonal antibody-mediated antitumor responses.